Hyperlipoproteinemias:
Indications for: Fenofibrate Tablets
Adjunct to diet: in severe hypertriglyceridemia; and to reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.
Adult Dosage:
Take with food. Hypertriglyceridemia: 54mg–160mg/day; adjust in 4–8 week intervals. Hypercholesterolemia, dyslipidemia: 160mg/day. Renal impairment (CrCl<50mL/min): initially 54mg/day. Discontinue if inadequate response after 2 months on max dose.
Children Dosage:
Not established.
Fenofibrate Tablets Contraindications:
Severe renal impairment. Dialysis. Active liver disease. Primary biliary cirrhosis. Unexplained persistent liver dysfunction. Gallbladder disease. Nursing mothers.
Fenofibrate Tablets Warnings/Precautions:
Renal impairment. Monitor CBCs for first year; monitor liver function, discontinue if ALT (SGPT) levels >3xULN persist. Discontinue if markedly elevated CPK levels, myopathy, or gallstones occur. Pregnancy.
See Also:
Fenofibrate Tablets Classification:
Fibrate.
Fenofibrate Tablets Interactions:
Avoid statins. Potentiates oral anticoagulants (monitor). Allow at least 1 hour before or 4–6 hours after bile acid sequestrants. Caution with immunosuppressants (eg, cyclosporine), other nephrotoxic drugs.
Adverse Reactions:
Abnormal liver function tests, elevated CPK, respiratory or GI effects, myopathy, cholelithiasis, pancreatitis, increased creatinine, rash; rare: rhabdomyolysis, transient hematologic changes, blood dyscrasias.
Note:
Formerly known under the brand name Lofibra.
How Supplied:
Contact supplier